Cardiovascular Drugs Market Global Scenario, Market Size, Outlook, Trend, and Forecast, 2016 – 2025

TABLE OF CONTENTS

Chapter 1        Prefix

1.1    Market Scope

1.2    Report Description

1.3    Research Methodology

1.3.1     Primary Research

1.3.2     Secondary Research

1.3.3     In-house Data Modeling

Chapter 2        Executive Summary

2.1   Global Cardiovascular Drugs Market Year-on-Year Growth, 2020 – 2028 (%)

Chapter 3        Market Outline

3.1    Market Inclination, Trend, Outlook and Viewpoint

3.2    Market Share Analysis: Company’s Competitive Scenario

3.3    Value Chain Analysis

3.4    Porter’s Five Forces Analysis

3.5    Market Dynamics

3.5.1     Drivers

3.5.1.1     Impact Analysis

3.5.2     Restraints

3.5.2.1     Impact Analysis

3.5.3     Opportunities

Chapter 4        Global Cardiovascular Drugs Market by Type: Market Size and Forecast, 2019 – 2028

4.1    Overview

4.2  Cardiac Failure Therapy

4.2.1   Current Trend and Analysis

4.2.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.2.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

4.3  Other Cardiovascular Type

4.3.1   Current Trend and Analysis

4.3.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.3.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

Chapter 5        Global Cardiovascular Drugs Market by Geography: Market Size and Forecast, 2019 - 2028 

5.1  Overview

5.1.1   Global Cardiovascular Drugs Market Year-on-Year Growth, by region 2016 – 2024 (%)

5.2  North America

5.2.1   Current Trend and Analysis

5.2.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.2.3   U.S.

5.2.3.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.2.3.2        By Type

5.2.4   Canada

5.2.4.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.2.4.2        By Type

5.2.5   Mexico

5.2.5.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.2.5.2        By Type

5.3    Europe

5.3.1   Current Trend and Analysis

5.3.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.3   UK

5.3.3.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.3.2        By Type

5.3.4   Russia

5.3.4.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.4.2        By Type

5.3.5   France

5.3.5.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.5.2        By Type

5.3.6   Italy

5.3.6.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.6.2        By Type

5.3.7   Germany

5.3.7.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.7.2        By Type

5.3.8   Rest of Europe

5.3.8.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.8.2        By Type

5.4    Asia-Pacific

5.4.1   Current Trend and Analysis

5.4.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.4.3   China

5.4.3.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.4.3.2        By Type

5.4.4   India

5.4.4.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.4.4.2        By Type

5.4.5   Japan

5.4.5.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.4.5.2        By Type

5.4.6   Rest of Asia-Pacific

5.4.6.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.4.6.2        By Type

5.5    RoW

5.5.1   Current Trend and Analysis

5.5.2   Market Size and Forecast

5.5.3   South America

5.5.3.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.5.3.2        By Type

5.5.4   Middle East

5.5.4.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.5.4.2        By Type

5.5.5   Africa

5.5.5.1        Market Size and Forecast, 2019 - 2028 ($ Billion)

5.5.5.2        By Type

Chapter 6        Company Profiles

6.1  Amgen

6.1.1     Company Overview

6.1.2     Product Portfolio

6.1.3     Business Strategies

6.1.4     Financials

6.1.5     Recent Developments

6.2  Astellas Pharma Inc.

6.2.1     Company Overview

6.2.2     Product Portfolio

6.2.3     Business Strategies

6.2.4     Financials

6.2.5     Recent Developments

6.3  Astrazeneca Plc

6.3.1     Company Overview

6.3.2     Product Portfolio

6.3.3     Business Strategies

6.3.4     Financials

6.3.5     Recent Developments

6.4  Boehringer Ingelheim GMBH

6.4.1     Company Overview

6.4.2     Product Portfolio

6.4.3     Business Strategies

6.4.4     Financials

6.4.5     Recent Developments

6.5  Brisol – Myers Squibb Company

6.5.1     Company Overview

6.5.2     Product Portfolio

6.5.3     Business Strategies

6.5.4     Financials

6.5.5     Recent Developments

6.6  Daiichi Sankyo Company Ltd.

6.6.1     Company Overview

6.6.2     Product Portfolio

6.6.3     Business Strategies

6.6.4     Financials

6.6.5     Recent Developments

6.7  Eli Lilly and Company

6.7.1     Company Overview

6.7.2     Product Portfolio

6.7.3     Business Strategies

6.7.4     Financials

6.7.5     Recent Developments

6.8  Gilead Sciences Inc.

6.8.1     Company Overview

6.8.2     Product Portfolio

6.8.3     Business Strategies

6.8.4     Financials

6.8.5     Recent Developments

6.9  GlaxoSmithKnile

6.9.1     Company Overview

6.9.2     Product Portfolio

6.9.3     Business Strategies

6.9.4     Financials

6.9.5     Recent Developments

6.10       Hikma Pharmaceutical Plc

6.10.1   Company Overview

6.10.2   Product Portfolio

6.10.3   Business Strategies

6.10.4   Financials

6.10.5   Recent Developments

6.11       Johnson & Johnson Inc.

6.11.1   Company Overview

6.11.2   Product Portfolio

6.11.3   Business Strategies

6.11.4   Financials

6.11.5   Recent Developments

6.12       Merck & Company Inc.

6.12.1   Company Overview

6.12.2   Product Portfolio

6.12.3   Business Strategies

6.12.4   Financials

6.12.5   Recent Developments

6.13       Novartis AG

6.13.1   Company Overview

6.13.2   Product Portfolio

6.13.3   Business Strategies

6.13.4   Financials

6.13.5   Recent Developments

6.14       Pfizer Inc.

6.14.1   Company Overview

6.14.2   Product Portfolio

6.14.3   Business Strategies

6.14.4   Financials

6.14.5   Recent Developments

6.15       Sanofi

6.15.1   Company Overview

6.15.2   Product Portfolio

6.15.3   Business Strategies

6.15.4   Financials

6.15.5   Recent Developments

6.16       United Therapeutic Corp.

6.16.1   Company Overview

6.16.2   Product Portfolio

6.16.3   Business Strategies

6.16.4   Financials

6.16.5   Recent Developments

Back to top

Payment Options

Single User $3897
Five User $5175
Enterprise $9135
Datapack $1299
Short Report: $1799